Pulmonary Hypertension Updates From 2018

Diagnosis of PAH

PAH Hemodynamic Definitions Have Changed Over Time

Exploring the New Hemodynamic Definition

Borderline mPAP (21 to 24 mmHg) is Associated With Increased Risk of PAH

New Definitions, More Patients Will Benefit

Risk Assessment and Classification of PAH

Clinical Classification of PH

Updated Clinical Classification of PH

Genetics and Genomics of PAH

PAH Risk Stratification

Achieving Low-Risk Status in PAH

Continuously Reassess and Get Patient to Goal

Registry Data Confirm Need for Early Diagnosis and Treatment Intensification

Treatment of PAH

3 Pathobiological Pathways in PAH

Treatment Strategy is Based on Risk Stratification

Algorithm for Treatment-Naive PAH Patient

Candidates for Monotherapy

Algorithm for Patient After Initial Treatment

Recommendations for Treatment Escalation in Patient on Background ERA + PDE5I

Place of Lung Transplantation in PAH Management

PAH Updates

High Level of Awareness for PAH

Algorithm for Diagnosing PH

Echocardiographic Signs of PH

Expert Centers Diagnosis and Follow-Up With Multidisciplinary Teams

Initial Risk Assessment Determines Initial Treatment

PAH Treatment Continuum

Updates in CTEPH

Natural History of Chronic Thromboembolic Pulmonary Hypertension

Incidence of CTEPH After an Acute PE

CTEPH Management

PEA is the Treatment of Choice for Operable Patients With CTEPH

Balloon Pulmonary Angioplasty for Inoperable CTEPH[a]

CHEST-1 Riociguat for the Treatment of CTEPH

MERIT-1 (Phase 2 Double-Blind Study) Macitentan in 80 Patients With Inoperable CTEPH

Summary

Management of CTEPH

Abbreviations

Abbreviations (cont)

Abbreviations (cont)